David Hardwicke, ESTEEM '17
Nick Swisher | August 24, 2018
Under the terms of the agreement, Medigene will supply Structured Immunity with a lead TCR candidate for a high-profile solid tumor target. Structured Immunity will evaluate the TCR’s specificity and recognition properties using their established structural immunology technologies. Structured Immunity, a Notre Dame startup and biotechnology company specializing in the optimization and validation of T cell receptor (TCR) proteins, and Medigene AG, a leading biotechnology company engaged in the development of immunotherapies for the treatment of cancer, today announced a research collaboration where Structured Immunity will provide structural immunology expertise in support of Medigene’s TCR discovery activities.
The agreement has formally established the relationship between the two companies with a view to further partnerships and collaborative opportunities in the future.
“We are delighted to begin this strategic collaboration with Medigene, a leader in immunotherapy, as together we aim to improve how lead TCR candidates are validated and optimized,” said David Hardwicke, co-founder and president at Structured Immunity. “We believe this partnership with Medigene will further showcase and validate our platform technology and demonstrate the value of structural immunology in TCR development.”
The collaboration will also involve the expertise of the research laboratory of Brian Baker, Ph.D., professor of structural biology at the University of Notre Dame, as well as the advice and support of Notre Dame’s IDEA Center.
Read more here.
Originally published by dailydomer.nd.edu on August 24, 2018.at